Senti Biosciences Inc ( SNTI ) shares are trading higher by 102.6% to $0.56 during Monday’s session after the company was awarded $8 million from the California Institute for Regenerative Medicines, which will support the ongoing development of SENTI-202.

The company says SENTI-202 is an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial aims to provide initial efficacy data by the end of 2024 and durability data in 2025.

Timothy Lu, CEO and Co-Founder of Senti Bio, expressed gratitude for CIRM’s support, highlighting SENTI-202’s potential to improve AML treatment. The trial, enrolling adult patients with specific hematologic malignancies in the US and Australia, evaluates two dose levels of SENTI-202 cells administered in cycles after disease-specific conditioning.

Read Also: What’s Going On With GameStop Stock Monday?

Is SNTI A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Senti Biosciences ( SNTI )‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Senti Biosciences ( SNTI ) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 14.97%, you'll need to buy a share of Global Net Lease by the Jul. 11, 2024. Once done, you can expect to receive a nominal payout of $0.28 on Jul. 16, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Senti Biosciences ( SNTI ) will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, SNTI has a 52-week high of $1.09 and a 52-week low of $0.21.